Role of LRP1 in Podocyte Biology
- Institution
- Yale University, CT
- Principal investigator
- Shuta Ishibe
- Funding
- $439K
- Duration
- 2012–2028
Moonbase score
Still being scored
Abstract
Project Summary Chronic kidney disease (CKD) often leads to irreversible deterioration of kidney function that often progresses to End Stage Kidney Disease (ESKD). CKD has emerged as a serious public health issue and data obtained from the USRDS reveals that 20 million patients in the United States suffer from CKD. As glomerular diseases secondary to podocyte dysfunction account for greater than 80% of all CKD, an intensive molecular and genetic approach to identify mechanisms for podocyte development, maintenance and repair may provide new therapeutic targets Previous evidence has suggested the importance of endocytic trafficking in podocytes, Using a unbiased screen, we have unearthed Lrp1 within clathrin coated vesicles, and as a potentially important gene to maintain the integrity of the glomerular filtration barrier. Loss of Lrp1 specifically in mice podocytes resulted in proteinuria and progression of CKD. Therefore, In Aim 1, we will define the fundamental mechanisms on how loss of Lrp1 contributes to podocyte dysfunction through characterizing the newly generated knockout mice. In Aim 2, we will determine how Lrp1 signaling plays a potential role in dsDNA repair by examining genes critical for nonhomologous end joining Setd1a and Lig4, and test SP16, a FDA approved Lrp1 agonist in the treatment of mouse models of glomerular injury.
LOADING MOONBASE SCORE
Questions for Yale University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Yale UniversityNot yet scored
Role of Calpains in Podocyte Biology
Shuta Ishibe · $332K · 2010–2026
- NIH · Yale University72
Multimodal imaging of prodromal synaptic, circuit, and network-level dysfunction in a murine model of Alzheimer's disease
Zhengxin Cai · $834K · 2022–2027
- NIH · Yale University69
Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer's disease.
Srikant Rangaraju · $949K · 2023–2026